Estrogen paradox in pulmonary hypertension: current controversies and future perspectives.
Estrogen paradox in pulmonary hypertension: current controversies and future perspectives.
复制标题
肺动脉高压中的雌激素悖论：当前的争议和未来的前景。
DOI：
10.1164/rccm.201201-0058pp
复制
发表时间：
2012
影响因子：
24.7
通讯作者：
Eghbali,Mansoureh
中科院分区：
文献类型：
--
作者：
Umar,Soban;Rabinovitch,Marlene;Eghbali,Mansoureh
尽管女性患者的肺动脉高压发生率较高，但许多实验研究表明，雌性动物的结局更好，卵巢切除术后疾病加重，雌激素具有强大的保护作用：这种现象被称为肺动脉高压的“雌激素悖论”。另一方面，一些临床研究间接地将雌激素与门脉高压的风险增加联系起来，而另一些研究则暗示雌激素代谢增加和某些雌激素代谢产物的高水平促进了家族性肺动脉高压的肺血管重塑。在这篇综述中，我们通过强调雌激素的不同受体介导的作用来研究雌激素悖论。虽然雌激素和雌激素受体为基础的治疗已显示出在挽救动物预先存在的肺动脉高压的承诺，他们的作用还没有被定义在人类。
Although the incidence of pulmonary hypertension is higher in female patients, numerous experimental studies have demonstrated better outcome in female animals, exacerbation of the disease after ovariectomy, and a strong protective effect of estrogen: a phenomenon known as the “estrogen paradox” of pulmonary hypertension. On the other hand, some clinical studies have indirectly linked estrogen to increased risk of portopulmonary hypertension, whereas others implicate increased estrogen metabolism and high levels of certain estrogen metabolites in promoting pulmonary vascular remodeling in familial pulmonary arterial hypertension. In this review we investigate the estrogen paradox through highlighting the differential receptor-mediated effects of estrogen. Although estrogen and estrogen receptor–based therapies have shown promise in rescuing preexisting pulmonary hypertension in animals, their role is yet to be defined in humans.